Literature DB >> 10494443

Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease.

M A Raskind1, E R Peskind, C Holmes, D S Goldstein.   

Abstract

BACKGROUND: High cerebrospinal fluid (CSF) norepinephrine (NE) concentrations in aging and Alzheimer's disease (AD) could reflect decreased NE clearance from central nervous system (CNS) extracellular fluid or increased release of NE into CNS extracellular fluid. Measuring CSF concentrations of the intraneuronal NE metabolite dihydroxyphenylglycol (DHPG), an estimate of NE clearance, and the NE precursor dihydroxyphenylacetic acid (DOPA), an estimate of NE biosynthesis, can help differentiate these mechanisms.
METHODS: NE, DHPG, and DOPA were determined by HPLC in CSF and plasma obtained following yohimbine, clonidine, and placebo. Ten AD, 10 older, and 11 young subjects were studied.
RESULTS: CSF DOPA following yohimbine was higher in older and AD than in young subjects. CSF DHPG did not differ among groups. Plasma DOPA following yohimbine was higher in AD than in young subjects.
CONCLUSIONS: During alpha-2 adrenoreceptor blockade in both aging and AD, there are increased responses of CNS NE biosynthesis and release with unchanged CNS NE clearance. This pattern is consistent with partial loss of CNS noradrenergic neurons with compensatory activation of remaining CNS noradrenergic neurons. Given the marked loss of locus coeruleus (LC) noradrenergic neurons in AD, achievement of high CSF NE suggests particularly prominent compensatory activation of remaining LC neurons in this disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494443     DOI: 10.1016/s0006-3223(99)00008-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  32 in total

1.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Authors:  Michael T Heneka; Fabian Nadrigny; Tommy Regen; Ana Martinez-Hernandez; Lucia Dumitrescu-Ozimek; Dick Terwel; Daniel Jardanhazi-Kurutz; Jochen Walter; Frank Kirchhoff; Uwe-Karsten Hanisch; Markus P Kummer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Determinants of central sympathetic activation in spontaneous primary subarachnoid hemorrhage.

Authors:  Michael Moussouttas; Edwin W Lai; John Khoury; Thanh T Huynh; Keith Dombrowski; Karel Pacak
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

3.  Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons.

Authors:  Dayong Wang; Eunice Y Yuen; Yuan Zhou; Zhen Yan; Yang K Xiang
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

4.  Bone density and brain atrophy in early Alzheimer's disease.

Authors:  Natalia Loskutova; Robyn A Honea; Eric D Vidoni; William M Brooks; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

5.  Arterial stiffness and the response to carotid sinus massage in older adults.

Authors:  Kenneth M Madden; Chris Lockhart; Karim Khan
Journal:  Aging Clin Exp Res       Date:  2010-02-05       Impact factor: 3.636

Review 6.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

7.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

Review 8.  Antipsychotic medications and the elderly: effects on cognition and implications for use.

Authors:  M J Byerly; M T Weber; D L Brooks; L R Snow; M A Worley; E Lescouflair
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

9.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 10.  Estrogen and Alzheimer's disease: the story so far.

Authors:  Brenna Cholerton; Carey E Gleason; Laura D Baker; Sanjay Asthana
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.